1. Dirençli Diyabetik Maküla Ödemi Tedavisinde Doz İntravitreal Triamsinolon ve Bevacizumab' in Görme Düzeyi ve Komplikasyonlar Açısından Karşılaştırılması.
- Author
-
SAĞDIK, Hacı Murat, ALPAY, Atilla, CANTÜRK UĞURBAŞ, Sılay, BÜYÜKUYSAL, Mustafa Üağatay, and UĞURBAŞ, Suat Hayri
- Subjects
- *
BEVACIZUMAB , *VISUAL acuity , *PEOPLE with diabetes , *DIABETES , *PATIENTS - Abstract
Objective: To compare the results of intravitreal triamsinolone (IVTA) and intravitreal bevacizumab (IVBE) injection for visual acuity and complications in treatment of diabetic macular edema (DMO). Materials and Methods: Sixty-two eyes of 62 patients were included in this study. The patients randomized in two groups and into 31 eyes, 4 mg/0.1 ml IVTA and into other 31 eyes 1.25 mg/0.0.5 ml IVBE were injected. The mean ages in IVTA and IVBE groups were 64±10 and 61.68±9.1 years respectively. Two groups were compared for the visual acuity changes, intraocular pressures changes and anterior and posterior segment complications. Results: The mean visual acuity increased significantly at 1 and 3 months when compared with preinjection values in the both groups. There was no statically differences between groups for pre and postoperative visual acuity. Any vision-threatening complications were not observed during follow-up examinations in the both groups. Conclusions: For the treatment of DMO, 4 mg/0.1 ml IVTA and 1.25 mg/0.05 ml IVBE injections were found to be effective and safe methods and there was no statistically significant differences between groups in terms of effectiveness and complications. [ABSTRACT FROM AUTHOR]
- Published
- 2012